Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles

ACS Appl Bio Mater. 2023 Feb 20;6(2):784-792. doi: 10.1021/acsabm.2c00965. Epub 2023 Jan 24.

Abstract

Radiation therapy has demonstrated promising effectiveness against several types of cancers. X-ray radiation therapy can be made further effective by utilizing nanoparticles of high-atomic-number (high-Z) materials that act as radiosensitizers. Here, in purpose of maximizing the radiation therapy within tumors, bovine serum albumin capped gadolinium oxide and gold nanoparticles (Gd2O3@BSA-Au NPs) are developed as a bimetallic radiosensitizer. In this study, we incorporate two high-Z-based nanoparticles, Au and Gd, in a single nanoplatform. The radiosensitizing ability of the nanoparticles was assessed with a series of in vitro tests, following evaluation in vivo in a breast cancer murine model. Enhanced tumor suppression is observed in the group that received radiation after administration of Gd2O3@BSA-Au NPs. As a result, cancer therapy efficacy is significantly improved by applying Gd2O3@BSA-Au NPs under X-ray irradiation, as evidenced by studies evaluating cell viability, proliferation, reactive oxygen species production, and in vivo anti-tumor effect.

Keywords: bimetallic; gadolinium; gold; nanoparticle; radiosensitizer; radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms / radiotherapy
  • Gadolinium / therapeutic use
  • Gold / pharmacology
  • Gold / therapeutic use
  • Metal Nanoparticles* / therapeutic use
  • Mice
  • Neoplasms*
  • Radiation-Sensitizing Agents* / pharmacology
  • Radiation-Sensitizing Agents* / therapeutic use
  • Serum Albumin, Bovine

Substances

  • Gadolinium
  • gadolinium oxide
  • Gold
  • Radiation-Sensitizing Agents
  • Serum Albumin, Bovine